跳至主要内容
临床试验/JPRN-UMIN000042040
JPRN-UMIN000042040已完成未知

Integrated genomic and epigenomic analysis of circulating tumor DNA from patients with malignant melanoma - COSMOS-MEL-01

ational Cancer Center Hospital East0 个研究点目标入组 50 人开始时间: 2020年10月7日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.A history of active malignancy within 5 years of disease-free status. However, patients with basal cell carcinoma or spinous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, endoscopically curable carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma equivalent lesions, or non-metastatic prostate cancer that does not require systemic treatment, who are judged to be cured by local treatment, will be enrolled in the registry if they are disease-free for 5 years or less It shall be possible. 2.Duplicate cancers are suspected on head, neck, thorax and abdomen and pelvic contrast CT scan within 60 days prior to enrollment. 3.Women who are pregnant. 4.Your physician determines that you are unsuitable for enrollment in this study.

研究者

发起方
ational Cancer Center Hospital East

相似试验